Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-120 (Kremezin) in Acute Kidney Disease
NCT07182422Phase 4
Key facts
- Status
- Recruiting
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Countries
- 1
- Sponsor
- Chang Gung Memorial Hospital
- Modality
- Small Molecules, Drug Delivery Systems
- Drugs
- activated charcoal
- Conditions
- acute kidney failure (AKF)
01
Overview
Phase 4, randomised, open-label trial of activated charcoal in acute kidney failure (AKF) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Change in serum indoxyl sulfate concentration at Day 180. Started Sep 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Experimental (AST-120 + Standard Care)
AST-120 (6g/day) + Standard post-AKD care
Control (Standard Care Only)
Standard post-AKD care only
03
Endpoints
Primary
Change in serum indoxyl sulfate concentration
Secondary
Change in serum p-cresyl sulfate concentration
Change in estimated glomerular filtration rate
Change in urine albumin/creatinine ratio
Change in urine total protein/creatinine ratio
Beyond the preview
Go deeper on NCT07182422.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182422.